Decision

Advertising investigations: February 2020

Decisions made by MHRA following investigations into complaints about advertising for licensed medicines.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 20 March 2020

Documents

February 2020 - Clinics advertising botulinum toxin products

MS Word Document, 23.7 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

February 2020 - Websites offering medicinal treatment services

MS Word Document, 23.7 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Contact [email protected] if you have concerns with the advertising of medicines or write to:

Advertising Standards Unit,
10 South Colonnade
Canary Wharf
London
E14 4PU

Alternatively, contact the pharmaceutical self-regulatory bodies, the Proprietary Association of Great Britain (PAGB) for advertising for over the counter medicines, or the Prescription Medicines Code of Practice Authority (PMCPA) for advertisements to health professionals for prescription medicines.

See the Blue Guide for guidance on how medicines should be promoted or advertised in the UK.

Published 20 March 2020